Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867048 · ClinicalTrials.gov registry record · Phase 4
Strategic Timing of Antiretroviral Treatment
A Phase 4 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 4
- Development phase
- 4,688
- Enrollment target
NCT00867048 is a Phase 4 study that has completed, run by University of Minnesota. The registered enrollment target is 4,688 participants.
The verdict
NCT00867048, a Phase 4 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4,688 participants
- Enrollment target
Study Summary
Objectives: * To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is good evidence for starting medicines. * To learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.
Interventions
- DRUG All licensed antiretroviral medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,688 participants |
| Start Date | 2009-04-15 |
| Est. Completion | 2022-07-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867048
The ClinicalTrials.gov registry entry for NCT00867048 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4,688 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which All licensed antiretroviral medications is the first listed.
NCT00867048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00867048 about?
NCT00867048 is a clinical study titled "Strategic Timing of Antiretroviral Treatment". Objectives: * To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is ...
What is the current status of trial NCT00867048?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4,688 participants. The study started on 2009-04-15. Estimated completion is 2022-07-27.
What interventions are being tested in trial NCT00867048?
The interventions under investigation include: All licensed antiretroviral medications (DRUG).
Who is sponsoring clinical trial NCT00867048?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.